Lipid raft, caveolin protein, and caveolar function modulation compounds and associated synthetic and therapeutic methods
First Claim
1. A method for treating HIV-associated dementia (HAD) or HIV-Encephalitis (HIVE) in a patient in need thereof, the method comprising administering an effective amount of a platinum (IV) compound effective for treating HIV-associated dementia (HAD) or HIV-Encephalitus (HIVE) to said patient, the platinum (IV) compound comprising the structure shown in at least one of formula (I), (II), (III), or (IV):
0 Assignments
0 Petitions
Accused Products
Abstract
The present invention is directed to the modulation of lipid rafts, caveolin proteins, or caveolar functions and processes by platinum(IV) compounds. Caveolae and/or lipid rafts are associated with cell transcription regulation, membrane and cellular transport, cell membrane receptor function, cellular trafficking, antigen presentation, cell differentiation and activation, cytokine modulation, membrane structure and function, and protein modulation. Caveolae, caveolin proteins and lipid rafts are known therapeutic targets for numerous biological functions. Diseases and disorders currently known to be therapeutically targeted through caveolae and/or lipid rafts include diabetes, cancer, cardiovascular diseases, atherosclerosis, pulmonary fibrosis, multiple sclerosis, viral and prion diseases, neuronal disorders, degenerative muscular dystrophies, and autoimmune disorders.
25 Citations
4 Claims
- 1. A method for treating HIV-associated dementia (HAD) or HIV-Encephalitis (HIVE) in a patient in need thereof, the method comprising administering an effective amount of a platinum (IV) compound effective for treating HIV-associated dementia (HAD) or HIV-Encephalitus (HIVE) to said patient, the platinum (IV) compound comprising the structure shown in at least one of formula (I), (II), (III), or (IV):
-
4. A method for treating HIV-associated dementia (HAD) or HIV-Encephalitis (HIVE) in a patient in need thereof, the method comprising administering an effective amount of a platinum (IV) compound effective for treating HIV-associated dementia (HAD) or HIV-Encephalitis (HIVE) to said patient, the platinum (IV) compound comprising the structure shown in at least one of formula (I), (II), (III), or (IV):
Specification